Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net Loss	$ (31,385)	$ (51,660)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash rent expense	0	(29)
Stock based compensation	5,220	16,618
Depreciation and amortization	322	204
Impairment loss on operating lease	66	136
Gain on sale of Legacy Assets	(78)	0
Loss on disposal of fixed assets	37	94
Change in the fair value of contingent consideration liabilities	1,578	0
Change in fair value of EIB loan	338	0
Non-cash goodwill impairment charge	0	825
Non-cash intangible impairment charge	5,900	0
Amortization of discount on available-for-sale investments	(2,019)	(113)
Change in deferred tax liabilities due to acquisition of Novosteo, Inc.	(248)	(284)
Changes in operating assets and liabilities, net of acquisitions:
Prepaid expenses and other current assets	4,246	2,580
Other assets	(9)	194
Accounts payable	(288)	(5,943)
Accrued expenses and other current liabilities	(1,972)	(6,660)
Net cash used in operating activities	(18,292)	(44,038)
Cash flow from investing activities:
Purchase of investments	(113,781)	(75,021)
Proceeds from maturities of investments	111,209	82,493
Cash acquired from Novosteo, Inc.	0	10,593
Advancement of notes receivable	(1,000)	0
Cash paid in acquisition of EryDel S.p.A. net of cash acquired	(2,116)	0
Proceeds from disposal of assets	90	70
Purchase of property and equipment	(160)	(133)
Net cash provided by (used in) investing activities	(5,758)	18,002
Cash flows from financing activities:
Payments of finance leases	(6)	(49)
Proceeds from issuance of common stock upon exercise of stock options	149	148
Proceeds from issuance of common stock in connection with open market sales agreement, net of issuance costs	0	608
Net cash provided by financing activities	143	707
Effect of exchange rate changes on cash	80	184
Net decrease in cash and cash equivalents	(23,827)	(25,145)
Cash and cash equivalents at beginning of period	44,579	69,724
Cash and cash equivalents at end of period	20,752	44,579
Supplemental disclosures of non-cash information:
Right-of-use assets obtained in exchange for new operating lease liabilities	0	411
Right-of-use asset and financing lease liability reduction as a result of lease modification	(70)	0
Right-of-use asset and operating lease liability reduction as a result of lease modification	0	(640)
EryDel
Supplemental disclosures of non-cash information:
Net assets acquired in exchange for common stock	63,732	0
Novosteo
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash goodwill impairment charge		800
Supplemental disclosures of non-cash information:
Net assets acquired in exchange for common stock	$ 0	$ 16,503